PCIA
BPMC

Prime Capital Investment Advisors’s Blueprint Medicines BPMC Stock Holding History

Prime Capital Investment Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,464
Closed -$320K – 935
2024
Q3 		$320K Sell
3,464
-6,476
-65% -$643K ﹤0.01% 711
2024
Q2 		$1.07M Buy
9,940
+5,171
+108% +$518K 0.02% 423
2024
Q1 		$452K Buy
+4,769
New +$409K 0.01% 645

Other funds holding BPMC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Prime Capital Investment Advisors's BPMC Position: Q4 2024 in Review

Prime Capital Investment Advisors sold out of Blueprint Medicines (BPMC) in Q4 2024, closing a stake of 3,464 shares — an estimated $320K sold.

Prime Capital Investment Advisors first reported a position in BPMC in Q1 2024 and held it in 3 quarters. The position peaked at $1.07M in Q2 2024. 345 funds tracked by Wall St. Rank hold BPMC as of Q4 2024.

  • Prime Capital Investment Advisors reported no remaining Blueprint Medicines position as of Q4 2024 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 3,464 Blueprint Medicines shares in Q4 2024, an estimated $320K.
  • Prime Capital Investment Advisors first reported a position in Blueprint Medicines in Q1 2024 and held it in 3 quarters.
  • Prime Capital Investment Advisors's Blueprint Medicines position peaked at $1.07M in Q2 2024.
  • 345 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2024.

Based on Prime Capital Investment Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.